Table 7.

Change in fatigue in lean, overweight and obese patients versus change in adipokines, IGF-1 and neuropeptides

Lean patients		∆MFIGF 30 wks	∆Adiponectin 30 wks	∆Leptin 30 wks	∆Resistin 30 wks	∆Free IGF-1 30 wks	∆Tot IGF-1 30 wks	∆IGFB3 30 wks	∆NPY 30 wks	∆NGF 30 wks
∆FIQ Fatigue 30 weeks	r P n	0.268 0.521 8	0.541 0.210 7	-0.432 0.333 7	-0.685 0.090 7	0.145 0.784 6	0.812 0.05 6	0.086 0.872 6	1.000 2	1.000 2
∆MFIGF 30 weeks	r P n	1.000 8	0.275 0.550 7	-0.220 0.635 7	-0.239 0.606 7	0.059 0.912 6	0.706 0.117 6	0.177 0.738 6	1.000 2	1.000 2
Overweight patients		∆MFIGF 30 wks	∆Adiponectin 30 wks	∆Leptin 30 wks	∆Resistin 30 wks	∆Free IGF-1 30 wks	∆Tot IGF-1 30 wks	∆IGFB3 30 wks	∆NPY 30 wks	∆NGF 30 wks
∆FIQ Fatigue 30 wks	r P n	0.530 0.008 24	-0.219 0.315 23	-0.099 0.654 23	0.270 0.213 23	-0.021 0.924 22	0.213 0.380 19	0.260 0.232 23	0.394 0.164 14	-0.475 0.086 14
∆MFIGF 30 wks	r P n	1.000 24	-0.089 0.685 23	0.127 0.562 23	-0.265 0.222 23	-0.233 0.297 22	-0.012 0.962 19	0.104 0.635 23	0.384 0.176 14	-0.047 0.874 14
Obese patients		∆MFIGF 30 wks	∆Adiponectin 30 wks	∆Leptin 30 wks	∆Resistin 30 wks	∆Free IGF-1 30 wks	∆Tot IGF-1 30 wks	∆IGFB3 30 wks	∆NPY 30 wks	∆NGF 30 wks
∆FIQ Fatigue 30 wks	r P n	0.283 0.373 12	-0.753 0.019 9	0.084 0.831 9	-0.326 0.391 9	-0.711 0.032 9	-0.261 0.498 9	0.072 0.878 7	0.154 0.805 5	-0.205 0.741 5
∆MFIGF 30 wks	r P n	1.000 12	-0.210 0.587 9	0.647 0.060 9	-0.815 0.007 9	-0.025 0.949 9	-0.418 0.263 9	0.786 0.036 7	-0.900 0.037 5	0.500 0.391 5

Correlation after 30 weeks between change (∆) in fatigue (∆FIQ and ∆MFIGF) and change in serum free IGF-1, serum levels of IGFB3, adipokines and neuropeptides in lean patients, overweight and obese patients. r, Spearman's correlation coefficient; P, P-value; n, number; FIQ, Fibromyalgia Impact Questionnaire; MFIGF, Multidimensional Fatigue Inventory subscale of General Fatigue; IGF, insulin-like growth factor; IGFB3, insulin-like growth factor-binding protein-3; NGF, nerve growth factor; NPY, neuropeptide Y.